Comment on: “Safety of Marketed Cancer Supportive Care Biosimilars in the U.S.: A Disproportionality Analysis Using the Food and Drug Administration Adverse Event Reporting System (FAERS) Database”
2020 ◽
Vol 76
(12)
◽
pp. 1775-1776
2017 ◽
Vol 16
(7)
◽
pp. 761-767
◽
2017 ◽
Vol 32
(8)
◽
pp. 1373-1376
◽